As Humira biosimilars take over the market, CVS has created a new ploy: the drug ‘rebate credit’

Taking stock of the drug industry, from the lab to the medicine chest

March 18, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Christine Kao/STAT STAT+ | As Humira biosimilars take over the market, CVS has created a new ploy: the drug 'rebate credit' With Humira biosimilars taking over the market, the PBM found a crafty way to keep as much money as possible. By Bob Herman STAT+ | FDA approves first gene therapy for a fatal neuron disease in children Orchard Therapeutics hopes its treatment for metachromatic leukodystrophy will save lives — and establish this form of gene therapy as profitable. By Jason Mast STAT+ | I was wrong about Geron's blood cancer drug. Now, is it a takeover target? For years, I've believed — and declared publicly — that Geron's effort to develop imetelstat would end in disappointment. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser